secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001193125-22-139069
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus prices upsized $75.6M public offering of 5.6M shares at $13.50/share
---------------------------------------------------------------------------

- Priced 5,600,000 shares of common stock at $13.50 per share for gross proceeds of $75.6M.
- Underwriters granted 30-day option to purchase up to 840,000 additional shares.
- Net proceeds expected to be ~$70.6M after underwriting discounts and expenses.
- Offering led by BofA Securities, Jefferies, Barclays, and Raymond James as joint book-runners.
- Closing expected on May 5, 2022, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000119312522139069/0001193125-22-139069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000119312522139069/d333422d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-139069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer